Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Shao, Haibo ^a   Ni, Yicheng ^b   Zhang, Jian ^c   Chen, Feng ^b   Dai, Xu ^a   Fan, Guoguang ^a   Sun, Ziping ^d   Xu, Ke ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Jiangsu Provincial Academy of Traditional Chinese Medicine   (China)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; GADODIAMIDE; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; FEMALE; HISTOPATHOLOGY; LIVER CANCER; MALE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; RABBIT; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; DIAGNOSTIC USE; DRUG EFFECTS; LIVER NEOPLASMS; PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; LIVER NEOPLASMS; MALE; RABBITS; TUMOR BURDEN;

EID: 84893486702     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082649     Document Type: Article

References (44)

1. Shojaei F (2012) Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 8: 1249-1254. doi: 10.1016/j.canlet.2012. 03.008.
2. Eichten A, Adler AP, Cooper B, Griffith J, Wei Y, et al. (2013) Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models. Angiogenesis 16: 429-441. doi: 10.1007/s10456-012-9328-3.
3. Wang YQ, Miao ZH (2013) Marine-Derived Angiogenesis Inhibitors for Cancer Therapy. Mar Drugs 11: 903-933. doi: 10.3390/md11030903.
4. Gaya AM, Rustin GJ (2005) Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol 17: 277-290.
5. Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, et al. (2008) Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 98: 388-398. doi: 10.1038/sj.bjc.6604168.
6. Salmon HW, Siemann DW (2006) Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 12: 4090-4094.
7. Siemann DW, Shi W (2008) Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 28: 2027-2031.
8. Kanthou C, Tozer GM (2009) Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 90: 284-294. doi: 10.1111/j.1365-2613.2009.00651.x.
9. Wang ES, Pili R, Seshadri M (2012) Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule. J Clin Oncol 30: 760-761. doi: 10.1200/JCO.2011.39.3934.
10. Palma MD, Nucera S (2012) Circulating endothelial progenitors and tumor resistance to vascular-targeting therapies. Cancer Discov 2: 395-397. doi: 10.1158/2159-8290.CD-12-0137.
11. Millward M, Mainwaring P, Mita A, Federico K, Lloyd GK, et al. (2012) Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Invest New Drugs 30: 1065-1073. doi: 10.1007/s10637-011-9642-4.
12. Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, et al. (2012) Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res 18: 3428-3439. doi: 10.1158/1078-0432.CCR-11-3376.
13. Ng QS, Mandeville H, Goh V, Alonzi R, Milner J, et al. (2012) Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol 23: 231-237. doi: 10.1093/annonc/mdr332.
14. Rajak H, Dewangan P K, Patel V, Jain DK, Singh A, et al. (2013) Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers. Curr Pharm Des 19: 1923-1955.
15. Sosa JA, Balkissoon J, Lu S, Langecker P, Elisei R, et al. (2012) Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery 152: 1078-1087. doi: 10.1016/j.surg.2012.08.036.
16. Baguley BC, McKeage MJ (2010) ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy. Future Oncol 6: 1537-1543. doi: 10.2217/fon.10.122.
17. Cummings J, Zweifel M, Smith N, Ross P, Peters J, et al. (2012) Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. Br J Cancer 106: 1766-1771. doi: 10.1038/bjc.2012.165.
18. Nathan P, Vinayan A (2013) Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma. Ther Adv Med Oncol 5: 119-131. doi: 10.1177/1758834012463624.
19. Nielsen T, Bentzen L, Pedersen M, Tramm T, Rijken PF, et al. (2012) Combretastatin A-4 Phosphate Affects Tumor Vessel Volume and Size Distribution as Assessed Using MRI-Based Vessel Size Imaging. Clin Cancer Res 18: 6469-6477. doi: 10.1158/1078-0432.CCR-12-2014.
20. Li J, Chen F, Feng Y, Cona MM, Yu J, et al. (2013) Diverse Responses to Vascular Disrupting Agent Combretastatin A4 Phosphate: A Comparative Study in Rats with Hepatic and Subcutaneous Tumor Allografts Using MRI Biomarkers, Microangiography, and Histopathology. Transl Oncol 6: 42-50.
21. O'Connor JPB, Jackson A, Parker GJM, Roberts C, Jayson GC (2012) Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 9: 167-177. doi: 10.1038/nrclinonc.2012.2.
22. Linnik IV, Williams SR, Davies KE, McGown AT, Hadfield JA, et al. (2012) Pre-clinical assessment of anti-vascular drugs using quantitative dynamic contrast-enhanced MRI. Int J Med Eng Inform 4: 362-372. doi: 10.1504/IJMEI.2012.050277.
23. Li SP, Padhani AR (2012) Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging 35: 745-763. doi: 10.1002/jmri.22838.
24. Chen F, Feng Y, Zheng K, De Keyzer F, Li J, et al. (2012) Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI. PLoS One 7: e41140. doi: 10.1371/journal.pone.0041140.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216.
26. Husband JE, Schwartz LH, Spencer J, Ollivier L, King DM, et al. (2004) Evaluation of the response to treatment of solid tumours-a consensus statement of the International Cancer Imaging Society. Br J Cancer 90: 2256-2260.
27. Wang H, Sun X, Chen F, De Keyzer F, Yu J, et al. (2009) Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 44: 44-53. doi: 10.1097/RLI.0b013e31818e5ace.
28. Padhani AR, Miles KA (2010) Multiparametric Imaging of Tumor Response to Therapy. Radiology 256: 348-364. doi: 10.1148/radiol.10091760.
29. Tozer GM (2003) Measuring tumour vascular response to antivascular and antiangiogenic drugs. Br J Radiol 76: S23-S35.
30. Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173: 83-91.
31. Yoon CJ, Chung JW, Park JH, Yoon YH, Lee JW, et al. (2003) Transcatheter Arterial Chemoembolization with Paclitaxel-Lipiodol Solution in Rabbit VX2 Liver Tumor. Radiology 229: 126-131.
32. Guo Y, Zhang Y, Jin N, Klein R, Nicolai J, et al. (2012) Electroporation-Mediated Transcatheter Arterial Chemoembolization (E-TACE) in the Rabbit VX2 Liver Tumor Model. Invest Radiol 47: 116-120. doi: 10.1097/RLI.0b013e31822e57cc.
33. Wijlemans JW, Deckers R, van den Bosch MA, Seinstra BA, van Stralen M, et al. (2013) Evolution of the Ablation Region After Magnetic Resonance-Guided High-Intensity Focused Ultrasound Ablation in a Vx2 Tumor Model. Invest Radiol 6: 381-386. doi: 10.1097/RLI.0b013e3182820257.
34. Li J, Cona MM, Chen F, Feng Y, Zhou L, et al. (2013) Sequential Systemic Administrations of Combretastatin A4 Phosphate and Radioiodinated Hypericin Exert Synergistic Targeted Theranostic Effects with Prolonged Survival on SCID Mice Carrying Bifocal Tumor Xenografts. Theranostics: 27-137. doi: 10.7150/thno.5790.
35. Li J, Oyen R, Verbruggen A, Ni Y (2013) Small molecule sequential dual-targeting theragnostic strategy (SMSDTTS): from preclinical experiments towards possible clinical anticancer applications. J Cancer 4: 133-145. doi: 10.7150/jca.5635.
36. Padhani AR, Husband JE (2001) Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 56: 607-620.
37. Dyke JP, Panicek DM, Healey JH, Meyers PA, Huvos AG, et al. (2003) Osteogenic and Ewing Sarcomas: Estimation of Necrotic Fraction during Induction Chemotherapy with Dynamic Contrast-enhanced MR Imaging. Radiology 228: 271-278.
38. Bihan DL, Breton E, Lallemand D, Aubin ML, Vignaud J, et al. (1988) Perfusion in intravoxel incoherent motion MR imaging. Radiology 168: 497-505.
39. Gadsby DC, Takeuchi A, Artigas P, Reyes N (2009) Peering into an ATPase ion pump with single-channel recordings. Philos Trans R Soc Lond B Biol Sci 3: 229-238. doi: 10.1098/rstb.2008.0243.
40. Prise VE, Honess DJ, Stratford MR, Wilson J, Tozer GM (2002) The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 21: 717-726.
41. Tozer GM, Kanthou C, Parkins CS, Hill SA (2002) The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83: 21-38.
42. Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, et al. (2010) A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 102: 1355-1360. doi: 10.1038/sj.bjc.6605650.
43. Thoeny HC, Keyzer FD, Chen F, Vandecaveye V, Verbeken EK, et al. (2005) Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 7: 779-987.
44. Li J, Sun Z, Zhang J, Shao H, Cona MM, et al. (2011) A dual-targeting anticancer approach: soil and seed principle. Radiology 260: 799-807. doi: 10.1148/radiol.11102120.